Challenges in Myelodysplastic Syndromes: Raising Awareness and Promoting New Insight in Therapeutic Options

Mufti G. , List A.F. , Gore S.D. . Myelodysplastic syndrome. Hematology Am Soc Hematol Educ Program. 2003: 176–199.

Greenberg P. . The myelodysplastic syndromes. In: Hoffman R. , Benz E.J. , Shattil S.J. , eds. Hematology: Basic Principles and Practice. 3rd ed. New York, NY: Churchill Livingstone; 2000: 1106–1129.

NCCN Clinical Practice Guidelines in Oncology. Myelodysplastic Syndromes. v2.2008. http://www.nccn.org/professionals/physician_gls/PDF/mds.pdf. Accessed July 15, 2008.

The Myelodysplastic Syndromes Foundation. http://www.mdsfoundation.org. Accessed July 15, 2008.

Fenaux P. , Mufti G.J. , Santini V. . Azacitidine (AZA) treatment prolongs overall survival (OS) in higher-risk MDS patients compared with conventional care regimens (CCR): results of the AZA-001 phase III study. Blood. 2007; 110: 250a. Abstract 817.

Kantarjian H.M. , O'Brien S. , Huang X. . Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience. Cancer. 2007; 109(6): 1133–1137.